Showing results (121-130 of 136) with videos related to
Sort By:
Pageof 14
Developmental Cell|September 16, 2021
Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formationNathaniel R Campbell, Anjali Rao, Miranda V Hunter, et al.European Journal of Cancer (Oxford, England : 1990)|August 14, 2022
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaJames Larkin, Jeffrey Weber, Michele Del Vecchio, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2015
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H I Andtbacka, Howard L Kaufman, Frances Collichio, et al.BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.The Lancet. Oncology|September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.European Journal of Cancer (Oxford, England : 1990)|March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and preventionAlexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2025
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)Michael K Wong, Mohammed M Milhem, Joseph J Sacco, et al.Nature Medicine|April 24, 2025
CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockadeGusztav Milotay, Martin Little, Robert A Watson, et al.European Journal of Cancer (Oxford, England : 1990)|March 2, 2020
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. TreatmentAlexander J Stratigos, Claus Garbe, Clio Dessinioti, et al.Pageof 14